Corporate changemakers are grappling with how to transform their social impact commitments into action, and many are encountering interference within their companies that can slow down progress and reduce impact.
We believe that corporate changemakers need renewed frameworks, tools and community to navigate this moment. In this conversation, four leaders from AARP, Bristol Myers Squibb, Merck, and Sanofi will share how they’ve applied learnings from FSG’s inaugural Purpose Studio to address headwinds and advance health equity strategies within their companies. Join us for an interactive discussion designed to help corporate changemakers diagnose interference and build enabling conditions for social impact strategies to thrive.
Speakers:
- Bobbi Silten, Chief of People & Culture and Managing Director, FSG
- Diana Blankman, Head, Corporate Social Responsibility, Sanofi US; President, Sanofi Cares N.A.
- Josette Gbemudu, Executive Director, U.S. Health Equity, Merck
- Nikhil Bumb, Managing Director, FSG
- Patricia Mae Doykos, Executive Director for Health Equity, Bristol Myers Squibb
- Reema Jweied-Guegel, Enterprise Strategic Partnerships Director, AARP
